Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
Novartis looks set to hand nisevokitug rights back to Xoma, though plenty of work on TGF-β continues.
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
Phase 1 data for divarasib in lung and colorectal cancers look good versus Lumakras and Krazati’s earlier showings.
A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.
With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.